Measuring severe adverse events and medication selection using a “PEER Report” for nonpsychotic patients: a retrospective chart review
Daniel A Hoffman,1 Charles DeBattista,2 Rob J Valuck,3 Dan V Iosifescu4
1Neuro-Therapy Clinic, Inc, Denver, CO, USA; 2Stanford University School of Medicine, Palo Alto, CA, USA; 3University of Colorado, SKAGES School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA; 4Mood and Anxiety Disorders Program, Mount Sinai School of Medicine, New York, NY, USA
Abstract: We previously reported on an objective new tool that uses quantitative electroencephalography (QEEG) normative- and referenced-electroencephalography sampling databases (currently called Psychiatric EEG Evaluation Registry [PEER]), which may assist physicians in determining medication selection for optimal efficacy to overcome trial-and-error prescribing. The PEER test compares drug-free QEEG features for individual patients to a database of patients with similar EEG patterns and known outcomes after pharmacological interventions. Based on specific EEG data elements and historical outcomes, the PEER Report may also serve as a marker of future severe adverse events (eg, agitation, hostility, aggressiveness, suicidality, homicidality, mania, hypomania) with specific medications. We used a retrospective chart review to investigate the clinical utility of such a registry in a naturalistic environment.
Results: This chart review demonstrated significant improvement on the global assessment scales Clinical Global Impression – Improvement and Quality of Life Enjoyment and Satisfaction – Short Form as well as time to maximum medical improvement and decreased suicidality occurrences. The review also showed that 54.5% of previous medications causing a severe adverse event would have been raised as a caution had the PEER Report been available at the time the drug was prescribed. Finally, due to the significant amount of off-label prescribing of psychotropic medications, additional, objective, evidence-based data aided the prescriber toward better choices.
Conclusion: The PEER Report may be useful, particularly in treatment-resistant patients, in helping to guide medication selection. Based on the preliminary data obtained from this chart review, additional studies are warranted to establish the safety and efficacy of adding PEER data when making medication decisions.
Keywords: PEER, referenced-EEG, QEEG, adverse events, medication selection, off label
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Other article by this author:
Hoffman DA, Schiller M, Greenblatt JM, Iosifescu DV
Published Date: 20 October 2011
Readers of this article also read:
Eduardo Pimenta, Suzanne Oparil
Published Date: 19 May 2009
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Noreddin AM, Elkhatib WF, Cunnion KM, Zhanel GG
Published Date: 7 October 2011
Adhvaryu MR, Vakharia BC
Published Date: 14 December 2011
Norling-Gustafsson A, Skaghammar K, Adolfsson A
Published Date: 16 December 2011
Al-Hazzaa HM, Musaiger AO; ATLS Research Group
Published Date: 20 December 2011
Lozano Ortiz R
Published Date: 11 June 2012
Longitudinal course of deficient emotional self-regulation CBCL profile in youth with ADHD: prospective controlled study
Biederman J, Spencer TJ, Petty C, Hyder LL, O'Connor KB, Surman CBH, Faraone SV
Published Date: 25 June 2012
Gaines KD, Hinson VK
Published Date: 2 July 2012
Copy number variants in a sample of patients with psychotic disorders: is standard screening relevant for actual clinical practice?
Van de Kerkhof NW, Feenstra I, van der Heijden FM, De Leeuw N, Pfundt R, Stöber G, Egger JI, Verhoeven WM
Published Date: 12 July 2012